StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)

Close on Nov 17, 2026Market cap $740.91MP/E –Yield –

Cytek Biosciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Cytek Biosciences's pe ratio was 574.0× on Apr 28, 2023, against 728.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 2023574.0×−202.0
2022Oct 31, 2022776.0×−40.0
2021Dec 31, 2021816.0×–

More Cytek Biosciences figures

See a number that looks wrong?